Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
News about Amgen Inc. (AMGN) centers on its biotechnology medicines, clinical milestones, corporate transactions and investor communications. The company describes itself as discovering, developing, manufacturing and delivering medicines for cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases, and its news flow reflects activity across these therapeutic areas.
Investors following AMGN news can see updates on regulatory decisions and clinical data for key products. Recent announcements include U.S. Food and Drug Administration approvals and label expansions, such as full approval for IMDELLTRA (tarlatamab-dlle) in extensive stage small cell lung cancer after progression on platinum-based chemotherapy, and approval of UPLIZNA (inebilizumab-cdon) for adults with generalized myasthenia gravis who are anti-acetylcholine receptor and anti-MuSK antibody positive. Amgen has also reported landmark cardiovascular outcomes data for Repatha (evolocumab) from the VESALIUS-CV trial.
Corporate development and pipeline news are another focus. Amgen has announced the acquisition of Dark Blue Therapeutics, a biotechnology company developing targeted protein degraders for oncology, adding an investigational MLLT1/3-targeting molecule for acute myeloid leukemia to its portfolio. The company also issues releases on capital allocation decisions, such as dividend declarations, and on participation in major healthcare investment conferences where management discusses business developments.
This AMGN news page allows readers to track company press releases and related coverage, including clinical trial readouts, FDA decisions, acquisitions, pricing and access initiatives, and presentations at scientific and investor meetings. Users interested in biotechnology, oncology innovation, cardiovascular outcomes and large-cap healthcare equities can monitor these updates as part of their ongoing research on Amgen stock.
Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference on March 11, 2026 at 9:20 a.m. ET. Peter Griffith, CFO, and Jasper van Grunsven, SVP of Rare Disease, will take part in a fireside chat. The event will be webcast live and archived for at least 90 days.
The webcast will be available to media, investors, and the public via Amgen's Investor Relations Events Calendar and archived on Amgen's website for replay.
Amgen (NASDAQ:AMGN) announced a $2.52 per share cash dividend for the second quarter of 2026. The Board declared the dividend on March 4, 2026, payable on June 5, 2026 to shareholders of record as of May 15, 2026.
Amgen (NASDAQ:AMGN) will present at the 46th Annual TD Cowen Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026. Senior VPs Kave Niksefat (Global Marketing and Access) and Justin Claeys (Finance) will speak.
The presentation will be webcast live and archived for at least 90 days on Amgen's Investor Relations events calendar and webcast page, available to media, investors and the public.
Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit on Wednesday, Feb. 18, 2026 at 12:15 p.m. PT. Jean-Charles Soria, senior vice president of oncology within global development, will deliver the presentation.
The presentation will be webcast live and archived for at least 90 days on Amgen's investor website, with timing and links listed on the Investor Relations Events Calendar.
Amgen (NASDAQ: AMGN) reported Q4 2025 and full-year results on Feb 3, 2026. Total revenues rose 10% year-over-year to $36.8 billion for 2025; product sales increased 10% to $35.15 billion. GAAP EPS was $14.23 for FY 2025 (up 88%); free cash flow was $8.1 billion. The company recorded a $1.2 billion Otezla intangible-asset impairment and reported mixed product performance, including strong growth for Repatha, TEZSPIRE and UPLIZNA and significant declines for Enbrel and other legacy products.
Amgen (NASDAQ:AMGN) will report fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after U.S. market close. A conference call with management will follow at 4:30 p.m. ET, and live audio webcast will be available on Amgen's Investor Relations site.
The webcast will be archived and available for replay for at least 90 days on the company's website.
Summary not available.
Amgen (NASDAQ:AMGN) will present at the 2026 J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Monday, January 12, 2026. Robert A. Bradway, chairman and chief executive officer, will deliver the presentation. The event will be webcast live and available to media, investors and the public via Amgen's website under Investors. Presentation times and webcast links are listed on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
Amgen (NASDAQ: AMGN) announced the acquisition of Dark Blue Therapeutics for up to $840 million on Jan 6, 2026. The deal brings DBT 3757, a MLLT1/3-targeted investigational degrader currently in IND-enabling studies, into Amgen's oncology portfolio for development in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Amgen plans to integrate Dark Blue into its research organization to accelerate clinical advancement. Investors backing Dark Blue included Oxford Science Enterprises, Bristol Myers Squibb, and Evotec; BofA served as financial advisor.
Amgen (NASDAQ: AMGN) announced on Jan 6, 2026 the acquisition of Dark Blue Therapeutics for up to $840 million. The deal adds an investigational small molecule that targets and degrades proteins MLLT1/3, aimed at specific types of acute myeloid leukemia (AML).
Preclinical leukemia models showed promising anti-cancer activity and a mechanism differentiated from current therapies, supporting potential single-agent and combination use to address treatment resistance and durability of remission. Amgen said it will integrate Dark Blue into its research organization to strengthen early oncology discovery and advance the program toward clinical investigation.